This HTML5 document contains 190 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01156/identifier/pubchem-substance/
n16http://linked.opendata.cz/resource/AHFS/
n19http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n31http://linked.opendata.cz/resource/drugbank/drug/DB01156/identifier/kegg-drug/
n9http://linked.opendata.cz/resource/drugbank/company/
n32http://linked.opendata.cz/resource/drugbank/drug/DB01156/identifier/drugbank/
n20http://linked.opendata.cz/resource/drugbank/dosage/
n27http://linked.opendata.cz/resource/drugbank/drug/DB01156/identifier/national-drug-code-directory/
n22http://www.drugs.com/
n24http://bio2rdf.org/drugbank:
n5http://linked.opendata.cz/resource/drugbank/drug/DB01156/identifier/chemspider/
n29http://www.pdrhealth.com/drugs/rx/
admshttp://www.w3.org/ns/adms#
n23http://www.rxlist.com/cgi/generic/
n7http://linked.opendata.cz/resource/drugbank/patent/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n4http://linked.opendata.cz/resource/drugbank/drug/DB01156/identifier/chebi/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n18http://linked.opendata.cz/ontology/mesh/
n6http://linked.opendata.cz/ontology/drugbank/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01156/identifier/wikipedia/
n14http://linked.opendata.cz/resource/drugbank/property/
n28http://linked.opendata.cz/resource/drugbank/drug/DB01156/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n30http://linked.opendata.cz/resource/drugbank/drug/DB01156/identifier/kegg-compound/
n17http://linked.opendata.cz/resource/atc/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01156/identifier/pubchem-compound/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01156
rdf:type
n6:Drug
n6:description
A unicyclic, aminoketone antidepressant. The mechanism of its therapeutic actions is not well understood, but it does appear to block dopamine uptake. The hydrochloride is available as an aid to smoking cessation treatment. [PubChem]
n6:dosage
n20:271B4B36-363D-11E5-9242-09173F13E4C5 n20:271B4B37-363D-11E5-9242-09173F13E4C5 n20:271B4B38-363D-11E5-9242-09173F13E4C5 n20:271B4B39-363D-11E5-9242-09173F13E4C5 n20:271B4B3A-363D-11E5-9242-09173F13E4C5 n20:271B4B3B-363D-11E5-9242-09173F13E4C5 n20:271B4B3C-363D-11E5-9242-09173F13E4C5 n20:271B4B3D-363D-11E5-9242-09173F13E4C5 n20:271B4B3E-363D-11E5-9242-09173F13E4C5 n20:271B4B3F-363D-11E5-9242-09173F13E4C5 n20:271B4B2A-363D-11E5-9242-09173F13E4C5 n20:271B4B2B-363D-11E5-9242-09173F13E4C5 n20:271B4B2C-363D-11E5-9242-09173F13E4C5 n20:271B4B2D-363D-11E5-9242-09173F13E4C5 n20:271B4B2E-363D-11E5-9242-09173F13E4C5 n20:271B4B2F-363D-11E5-9242-09173F13E4C5 n20:271B4B30-363D-11E5-9242-09173F13E4C5 n20:271B4B31-363D-11E5-9242-09173F13E4C5 n20:271B4B32-363D-11E5-9242-09173F13E4C5 n20:271B4B33-363D-11E5-9242-09173F13E4C5 n20:271B4B34-363D-11E5-9242-09173F13E4C5 n20:271B4B35-363D-11E5-9242-09173F13E4C5
n6:generalReferences
# Fryer JD, Lukas RJ: Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther. 1999 Jan;288(1):88-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9862757 # Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA: 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005;7(3):106-13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16027765 # Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, VanMeter S, Harriett AE, Wang Y: Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005 Aug;66(8):974-81. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16086611 # : Annual report on the results of treatment in gynecological cancer. Twenty-first volume. Statements of results obtained in patients treated in 1982 to 1986, inclusive 3 and 5-year survival up to 1990. Int J Gynaecol Obstet. 1991 Sep;36 Suppl:1-315. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1684162 # Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA: A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol. 2006 Oct;26(5):482-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16974189
n6:group
approved
n6:halfLife
24 hours
n6:indication
For the treatment of depression and as aid to smoking cessation.
owl:sameAs
n11:DB01156 n24:DB01156
dcterms:title
Bupropion
adms:identifier
n4:3219 n5:431 n12:Bupropion n25:444 n26:46506896 n27:0179-0022-44 n28:PA448687 n30:C06860 n31:D07591 n32:DB01156
n6:mechanismOfAction
Bupropion selectively inhibits the neuronal reuptake of dopamine, norepinephrine, and serotonin; actions on dopaminergic systems are more significant than imipramine or amitriptyline whereas the blockade of norepinephrine and serotonin reuptake at the neuronal membrane is weaker for bupropion than for tricyclic antidepressants. The increase in norepinephrine may attenuate nicotine withdrawal symptoms and the increase in dopamine at neuronal sites may reduce nicotine cravings and the urge to smoke. Bupropion exhibits moderate anticholinergic effects.
n6:packager
n9:271B4B07-363D-11E5-9242-09173F13E4C5 n9:271B4B08-363D-11E5-9242-09173F13E4C5 n9:271B4AEA-363D-11E5-9242-09173F13E4C5 n9:271B4B09-363D-11E5-9242-09173F13E4C5 n9:271B4B05-363D-11E5-9242-09173F13E4C5 n9:271B4B06-363D-11E5-9242-09173F13E4C5 n9:271B4B04-363D-11E5-9242-09173F13E4C5 n9:271B4AF0-363D-11E5-9242-09173F13E4C5 n9:271B4AF3-363D-11E5-9242-09173F13E4C5 n9:271B4AF4-363D-11E5-9242-09173F13E4C5 n9:271B4AF1-363D-11E5-9242-09173F13E4C5 n9:271B4AF2-363D-11E5-9242-09173F13E4C5 n9:271B4AFB-363D-11E5-9242-09173F13E4C5 n9:271B4AFC-363D-11E5-9242-09173F13E4C5 n9:271B4AF9-363D-11E5-9242-09173F13E4C5 n9:271B4AFA-363D-11E5-9242-09173F13E4C5 n9:271B4AFF-363D-11E5-9242-09173F13E4C5 n9:271B4B00-363D-11E5-9242-09173F13E4C5 n9:271B4AFD-363D-11E5-9242-09173F13E4C5 n9:271B4AFE-363D-11E5-9242-09173F13E4C5 n9:271B4AEB-363D-11E5-9242-09173F13E4C5 n9:271B4AEC-363D-11E5-9242-09173F13E4C5 n9:271B4AE8-363D-11E5-9242-09173F13E4C5 n9:271B4AE9-363D-11E5-9242-09173F13E4C5 n9:271B4AEF-363D-11E5-9242-09173F13E4C5 n9:271B4AF8-363D-11E5-9242-09173F13E4C5 n9:271B4AED-363D-11E5-9242-09173F13E4C5 n9:271B4AEE-363D-11E5-9242-09173F13E4C5 n9:271B4B03-363D-11E5-9242-09173F13E4C5 n9:271B4B01-363D-11E5-9242-09173F13E4C5 n9:271B4B02-363D-11E5-9242-09173F13E4C5 n9:271B4AD2-363D-11E5-9242-09173F13E4C5 n9:271B4AD3-363D-11E5-9242-09173F13E4C5 n9:271B4AD0-363D-11E5-9242-09173F13E4C5 n9:271B4AD1-363D-11E5-9242-09173F13E4C5 n9:271B4AD6-363D-11E5-9242-09173F13E4C5 n9:271B4AD7-363D-11E5-9242-09173F13E4C5 n9:271B4AD4-363D-11E5-9242-09173F13E4C5 n9:271B4AD5-363D-11E5-9242-09173F13E4C5 n9:271B4ACB-363D-11E5-9242-09173F13E4C5 n9:271B4ACE-363D-11E5-9242-09173F13E4C5 n9:271B4ACF-363D-11E5-9242-09173F13E4C5 n9:271B4ACC-363D-11E5-9242-09173F13E4C5 n9:271B4ACD-363D-11E5-9242-09173F13E4C5 n9:271B4AE2-363D-11E5-9242-09173F13E4C5 n9:271B4AE3-363D-11E5-9242-09173F13E4C5 n9:271B4AE0-363D-11E5-9242-09173F13E4C5 n9:271B4AE1-363D-11E5-9242-09173F13E4C5 n9:271B4AE6-363D-11E5-9242-09173F13E4C5 n9:271B4AE7-363D-11E5-9242-09173F13E4C5 n9:271B4AE4-363D-11E5-9242-09173F13E4C5 n9:271B4AE5-363D-11E5-9242-09173F13E4C5 n9:271B4ADA-363D-11E5-9242-09173F13E4C5 n9:271B4ADB-363D-11E5-9242-09173F13E4C5 n9:271B4AD8-363D-11E5-9242-09173F13E4C5 n9:271B4AD9-363D-11E5-9242-09173F13E4C5 n9:271B4ADE-363D-11E5-9242-09173F13E4C5 n9:271B4ADF-363D-11E5-9242-09173F13E4C5 n9:271B4ADC-363D-11E5-9242-09173F13E4C5 n9:271B4ADD-363D-11E5-9242-09173F13E4C5 n9:271B4AF7-363D-11E5-9242-09173F13E4C5 n9:271B4AF5-363D-11E5-9242-09173F13E4C5 n9:271B4AF6-363D-11E5-9242-09173F13E4C5
n6:patent
n7:5358970 n7:2524300 n7:2168364 n7:7241805
n6:routeOfElimination
Bupropion is extensively metabolized in humans. Oxidation of the bupropion side chain results in the formation of a glycine conjugate of metachlorobenzoic acid, which is then excreted as the major urinary metabolite. Following oral administration of 200 mg of 14C-bupropion in humans, 87% and 10% of the radioactive dose were recovered in the urine and feces, respectively. However, the fraction of the oral dose of bupropion excreted unchanged was only 0.5%, a finding consistent with the extensive metabolism of bupropion.
n6:synonym
Bupropion Amfebutamone
n6:toxicity
Symptoms of overdose include seizures, hallucinations, loss of consciousness, tachycardia, and cardiac arrest.
n15:hasAHFSCode
n16:28-16-04-92
n6:foodInteraction
Take without regard to meals. Avoid St.John's Wort. Avoid alcohol.
n6:proteinBinding
84 %
n6:salt
n6:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Amfebutamone.htm
n18:hasConcept
n19:M0025361
foaf:page
n22:bupropion.html n23:wellbutrin.htm n29:rx-mono.aspx?contentFileName=Wel1488.html&contentName=Wellbutrin&contentId=637
n6:IUPAC-Name
n14:271B4B44-363D-11E5-9242-09173F13E4C5
n6:InChI
n14:271B4B4A-363D-11E5-9242-09173F13E4C5
n6:Molecular-Formula
n14:271B4B49-363D-11E5-9242-09173F13E4C5
n6:Molecular-Weight
n14:271B4B46-363D-11E5-9242-09173F13E4C5
n6:Monoisotopic-Weight
n14:271B4B47-363D-11E5-9242-09173F13E4C5
n6:SMILES
n14:271B4B48-363D-11E5-9242-09173F13E4C5
n6:Water-Solubility
n14:271B4B42-363D-11E5-9242-09173F13E4C5 n14:271B4B5A-363D-11E5-9242-09173F13E4C5
n6:logP
n14:271B4B40-363D-11E5-9242-09173F13E4C5 n14:271B4B43-363D-11E5-9242-09173F13E4C5 n14:271B4B5C-363D-11E5-9242-09173F13E4C5
n6:logS
n14:271B4B41-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n17:N06AX12
n6:H-Bond-Acceptor-Count
n14:271B4B50-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Donor-Count
n14:271B4B51-363D-11E5-9242-09173F13E4C5
n6:InChIKey
n14:271B4B4B-363D-11E5-9242-09173F13E4C5
n6:Polar-Surface-Area--PSA-
n14:271B4B4C-363D-11E5-9242-09173F13E4C5
n6:Polarizability
n14:271B4B4E-363D-11E5-9242-09173F13E4C5
n6:Refractivity
n14:271B4B4D-363D-11E5-9242-09173F13E4C5
n6:Rotatable-Bond-Count
n14:271B4B4F-363D-11E5-9242-09173F13E4C5
n6:absorption
For sustained release, peak plasma concentrations are achieved within 3 hours.
n6:affectedOrganism
Humans and other mammals
n6:casRegistryNumber
34841-39-9
n6:category
n6:containedIn
n8:271B4B0A-363D-11E5-9242-09173F13E4C5 n8:271B4B19-363D-11E5-9242-09173F13E4C5 n8:271B4B1A-363D-11E5-9242-09173F13E4C5 n8:271B4B17-363D-11E5-9242-09173F13E4C5 n8:271B4B18-363D-11E5-9242-09173F13E4C5 n8:271B4B1D-363D-11E5-9242-09173F13E4C5 n8:271B4B1E-363D-11E5-9242-09173F13E4C5 n8:271B4B1B-363D-11E5-9242-09173F13E4C5 n8:271B4B1C-363D-11E5-9242-09173F13E4C5 n8:271B4B0D-363D-11E5-9242-09173F13E4C5 n8:271B4B0E-363D-11E5-9242-09173F13E4C5 n8:271B4B0B-363D-11E5-9242-09173F13E4C5 n8:271B4B0C-363D-11E5-9242-09173F13E4C5 n8:271B4B11-363D-11E5-9242-09173F13E4C5 n8:271B4B16-363D-11E5-9242-09173F13E4C5 n8:271B4B0F-363D-11E5-9242-09173F13E4C5 n8:271B4B10-363D-11E5-9242-09173F13E4C5 n8:271B4B29-363D-11E5-9242-09173F13E4C5 n8:271B4B27-363D-11E5-9242-09173F13E4C5 n8:271B4B28-363D-11E5-9242-09173F13E4C5 n8:271B4B21-363D-11E5-9242-09173F13E4C5 n8:271B4B22-363D-11E5-9242-09173F13E4C5 n8:271B4B1F-363D-11E5-9242-09173F13E4C5 n8:271B4B20-363D-11E5-9242-09173F13E4C5 n8:271B4B25-363D-11E5-9242-09173F13E4C5 n8:271B4B26-363D-11E5-9242-09173F13E4C5 n8:271B4B23-363D-11E5-9242-09173F13E4C5 n8:271B4B24-363D-11E5-9242-09173F13E4C5 n8:271B4B14-363D-11E5-9242-09173F13E4C5 n8:271B4B15-363D-11E5-9242-09173F13E4C5 n8:271B4B12-363D-11E5-9242-09173F13E4C5 n8:271B4B13-363D-11E5-9242-09173F13E4C5
n6:Bioavailability
n14:271B4B56-363D-11E5-9242-09173F13E4C5
n6:Ghose-Filter
n14:271B4B58-363D-11E5-9242-09173F13E4C5
n6:MDDR-Like-Rule
n14:271B4B59-363D-11E5-9242-09173F13E4C5
n6:Melting-Point
n14:271B4B5B-363D-11E5-9242-09173F13E4C5
n6:Number-of-Rings
n14:271B4B55-363D-11E5-9242-09173F13E4C5
n6:Physiological-Charge
n14:271B4B54-363D-11E5-9242-09173F13E4C5
n6:Rule-of-Five
n14:271B4B57-363D-11E5-9242-09173F13E4C5
n6:Traditional-IUPAC-Name
n14:271B4B45-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-acidic-
n14:271B4B52-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-basic-
n14:271B4B53-363D-11E5-9242-09173F13E4C5